ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy

Molecular Therapy

Volumn 20, Issue 1, 2012, Pages 28-36

  Verma, Amrisha ^a   Shan, Zhiying ^b   Lei, Bo ^c   Yuan, Lihui ^b   Liu, Xuan ^a   Nakagawa, Takahiko ^d   Grant, Maria B ^b   Lewin, Alfred S ^b   Hauswirth, William W ^a   Raizada, Mohan K ^b   Li, Qiuhong ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN[1-7]; MESSENGER RNA; PARVOVIRUS VECTOR;

ANGIOTENSIN II GENE; ANGIOTENSIN[1-7] GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; GENE; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPRAGUE DAWLEY RAT; VIRAL GENE THERAPY;

ADENO-ASSOCIATED VIRUS; MUS; RATTUS;

EID: 84856947590     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.155     Document Type: Article

References (48)

1. Cheung, N, Mitchell, P and Wong, TY (2010). Diabetic retinopathy. Lancet 376: 124-136.
2. Mehta, PK and Griendling, KK (2007). Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol, Cell Physiol 292: C82-C97. (Pubitemid 46127306)
3. Marchesi, C, Paradis, P and Schiffrin, EL (2008). Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 29: 367-374.
4. de Cavanagh, EM, Inserra, F, Ferder, M and Ferder, L (2007). From mitochondria to disease: role of the renin-angiotensin system. Am J Nephrol 27: 545-553. (Pubitemid 350014941)
5. de Cavanagh, EM, Ferder, M, Inserra, F and Ferder, L (2009). Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint. Am J Physiol Heart Circ Physiol 296: H550-H558.
6. Danser, AH, van den Dorpel, MA, Deinum, J, Derkx, FH, Franken, AA, Peperkamp, E et al. (1989). Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 68: 160-167. (Pubitemid 19028740)
7. Danser, AH, Derkx, FH, Admiraal, PJ, Deinum, J, de Jong, PT and Schalekamp, MA (1994). Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 35: 1008-1018. (Pubitemid 24079832)
8. Deinum, J, Derkx, FH, Danser, AH and Schalekamp, MA (1990). Identification and quantification of renin and prorenin in the bovine eye. Endocrinology 126: 1673-1682. (Pubitemid 20095779)
9. Paul, M, Poyan Mehr, A and Kreutz, R (2006). Physiology of local renin-angiotensin systems. Physiol Rev 86: 747-803. (Pubitemid 44033382)
10. Fletcher, EL, Phipps, JA, Ward, MM, Vessey, KA and Wilkinson-Berka, JL (2010). The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. Prog Retin Eye Res 29: 284-311.
11. Tikellis, C, Johnston, CI, Forbes, JM, Burns, WC, Thomas, MC, Lew, RA et al. (2004). Identification of angiotensin converting enzyme 2 in the rodent retina. Curr Eye Res 29: 419-427. (Pubitemid 40138381)
12. Zhang, JZ, Gao, L, Widness, M, Xi, X and Kern, TS (2003). Captopril inhibits glucose accumulation in retinal cells in diabetes. Invest Ophthalmol Vis Sci 44: 4001-4005. (Pubitemid 37047975)
13. Zhang, JZ, Xi, X, Gao, L and Kern, TS (2007). Captopril inhibits capillary degeneration in the early stages of diabetic retinopathy. Curr Eye Res 32: 883-889. (Pubitemid 350034786)
14. Moravski, CJ, Skinner, SL, Stubbs, AJ, Sarlos, S, Kelly, DJ, Cooper, ME et al. (2003). The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. Am J Pathol 162: 151-160. (Pubitemid 36041997)
15. Phipps, JA, Wilkinson-Berka, JL and Fletcher, EL (2007). Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol. Invest Ophthalmol Vis Sci 48: 927-934. (Pubitemid 351260731)
16. Wilkinson-Berka, JL, Tan, G, Jaworski, K and Ninkovic, S (2007). Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina. Am J Hypertens 20: 423-430. (Pubitemid 46441750)
17. Chaturvedi, N, Porta, M, Klein, R, Orchard, T, Fuller, J, Parving, HH et al.; DIRECT Programme Study Group. (2008). Effect of candesartan on prevention (DIRECTPrevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 372: 1394-1402.
18. Sj́ie, AK, Klein, R, Porta, M, Orchard, T, Fuller, J, Parving, HH et al.; DIRECT Programme Study Group. (2008). Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 372: 1385-1393.
19. Mauer, M, Zinman, B, Gardiner, R, Suissa, S, Sinaiko, A, Strand, T et al. (2009). Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361: 40-51.
20. Ghattas, A, Lip, PL and Lip, GY (2011). Renin-angiotensin blockade in diabetic retinopathy. Int J Clin Pract 65: 113-116.
21. Wright, AD and Dodson, PM (2010). Diabetic retinopathy and blockade of the renin-angiotensin system: new data from the DIRECT study programme. Eye (Lond) 24: 1-6.
22. Miyazaki, M and Takai, S (2006). Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J Pharmacol Sci 100: 391-397. (Pubitemid 44609530)
23. Cristovam, PC, Arnoni, CP, de Andrade, MC, Casarini, DE, Pereira, LG, Schor, N et al. (2008). ACE-dependent and chymase-dependent angiotensin II generation in normal and glucose-stimulated human mesangial cells. Exp Biol Med (Maywood) 233: 1035-1043.
24. Kumar, R and Boim, MA (2009). Diversity of pathways for intracellular angiotensin II synthesis. Curr Opin Nephrol Hypertens 18: 33-39.
25. Shiota, N, Saegusa, Y, Nishimura, K and Miyazaki, M (1997). Angiotensin II-generating system in dog and monkey ocular tissues. Clin Exp Pharmacol Physiol 24: 243-248. (Pubitemid 27187407)
26. Nguyen, G, Delarue, F, Burckl C, Bouzhir, L, Giller, T and Sraer, JD (2002). Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109: 1417-1427. (Pubitemid 34596167)
27. Ferreira, AJ, Santos, RA, Bradford, CN, Mecca, AP, Sumners, C, Katovich, MJ et al. (2010). Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension 55: 207-213.
28. Ferrario, CM, Trask, AJ and Jessup, JA (2005). Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 289: H2281-H2290. (Pubitemid 41698533)
29. Sica, DA (2002). The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors. J Renin Angiotensin Aldosterone Syst 3: 66-71. (Pubitemid 34966175)
30. Perret-Guillaume, C, Joly, L, Jankowski, P and Benetos, A (2009). Benefits of the RAS blockade: clinical evidence before the ONTARGET study. J Hypertens Suppl 27: S3-S7.
31. Ribeiro-Oliveira, A Jr, Nogueira, AI, Pereira, RM, Boas, WW, Dos Santos, RA and Sims e Silva, AC (2008). The renin-angiotensin system and diabetes: an update. Vasc Health Risk Manag 4: 787-803.
32. Perkins, JM and Davis, SN (2008). The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control. Curr Opin Endocrinol Diabetes Obes 15: 147-152. (Pubitemid 351674095)
33. Keidar, S, Kaplan, M and Gamliel-Lazarovich, A (2007). ACE2 of the heart: From angiotensin I to angiotensin (1-7). Cardiovasc Res 73: 463-469. (Pubitemid 46091776)
34. Iwai, M and Horiuchi, M (2009). Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens Res 32: 533-536.
35. Der Sarkissian, S, Huentelman, MJ, Stewart, J, Katovich, MJ and Raizada, MK (2006). ACE2: A novel therapeutic target for cardiovascular diseases. Prog Biophys Mol Biol 91: 163-198. (Pubitemid 43288989)
36. Huentelman, MJ, Grobe, JL, Vazquez, J, Stewart, JM, Mecca, AP, Katovich, MJ et al. (2005). Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 90: 783-790. (Pubitemid 41406067)
37. HernÁdez Prada, JA, Ferreira, AJ, Katovich, MJ, Shenoy, V, Qi, Y, Santos, RA et al. (2008). Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 51: 1312-1317. (Pubitemid 351555943)
38. Ferreira, AJ, Shenoy, V, Yamazato, Y, Sriramula, S, Francis, J, Yuan, L et al. (2009). Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 179: 1048-1054.
39. Fraga-Silva, RA, Sorg, BS, Wankhede, M, Dedeugd, C, Jun, JY, Baker, MB et al. (2010). ACE2 activation promotes antithrombotic activity. Mol Med 16: 210-215.
40. Der Sarkissian, S, Grobe, JL, Yuan, L, Narielwala, DR, Walter, GA, Katovich, MJ et al. (2008). Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 51: 712-718. (Pubitemid 351301525)
41. Li, Q, Verma, A, Han, PY, Nakagawa, T, Johnson, RJ, Grant, MB et al. (2010). Diabetic eNOS-knockout mice develop accelerated retinopathy. Invest Ophthalmol Vis Sci 51: 5240-5246.
42. Huentelman, MJ, Zubcevic, J, Katovich, MJ and Raizada, MK (2004). Cloning and characterization of a secreted form of angiotensin-converting enzyme 2. Regul Pept 122: 61-67. (Pubitemid 39233638)
43. Dawn-Linsley, M, Ekinci, FJ, Ortiz, D, Rogers, E and Shea, TB (2005). Monitoring thiobarbituric acid-reactive substances (TBARs) as an assay for oxidative damage in neuronal cultures and central nervous system. J Neurosci Methods 141: 219-222. (Pubitemid 40126660)
44. Nakagawa, T, Sato, W, Glushakova, O, Heinig, M, Clarke, T, Campbell-Thompson, M et al. (2007). Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 18: 539-550. (Pubitemid 46193319)
45. Ferrario, CM, Chappell, MC, Tallant, EA, Brosnihan, KB and Diz, DI (1997). Counterregulatory actions of angiotensin-(1-7). Hypertension 30(3 Pt 2): 535-541. (Pubitemid 27444228)
46. Lorenz, JN (2010). Chymase: the other ACE? Am J Physiol Renal Physiol 298: F35-F36.
47. Hauswirth WW, Li Q, Raisler B, Timmers AM, Berns KI, Flannery JG, LaVail MM and Lewin AS (2004). Range of retinal diseases potentially treatable by AAV-vectored gene therapy. Novartis Found Symp 255: 179-188; discussion 188-194. (Pubitemid 44844413)
48. Herzog, RW, Cao, O and Srivastava, A (2010). Two decades of clinical gene therapy-success is finally mounting. Discov Med 9: 105-111.